Maastricht University Medical Center
mumc.nlTotal trials
843
Active
100
Phase 3
25
Total enrollment
225,666
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fluorometholone 0.1% Oph Susp | — | — | — | — | — | 1 | |
| Dexamethasone 0.1% ophthalmic suspension | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| standard step-up care | — | — | — | — | — | 1 | |
| 5FU-Calcipotriol | — | — | — | — | — | 1 | |
| 5-FU 50 MG/ML Topical Cream | — | — | — | — | — | 1 | |
| Cobicistat | — | — | — | — | — | 1 | |
| Fluconazole | — | — | — | — | 2 | ||
| Osimertinib & febuxostat | — | — | — | — | — | 1 | |
| Tarlatamab | — | — | — | — | — | 1 | |
| CP-506 | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Immune checkpoint inhibitor | — | — | — | — | — | 1 | |
| Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab | — | — | — | — | — | 1 | |
| Biobanking of biomaterial for future genetic research. | — | — | — | — | — | 1 | |
| Vismodegib | — | — | — | — | — | 1 | |
| Sonidegib | — | — | — | — | — | 1 | |
| Isolation of tumor DNA | — | — | — | — | — | 1 | |
| Venous blood sampling prior to CCTA. | — | — | — | — | — | 1 |
Next readouts
- 2024-03
- 2024-05
- 2025-12
- 2026-04-22
- 2026-06
- 2026-06-01
- 2026-11-01
- 2027-02
- 2027-06
- 2028-09
Top conditions
- Obesity53
- Healthy19
- Breast Cancer17
- Insulin Resistance17
- Overweight and Obesity15
- Sarcopenia15
- Overweight14
- Irritable Bowel Syndrome14
Frequently asked questions about Maastricht University Medical Center
- How many clinical trials does Maastricht University Medical Center have on ClinicalTrials.gov?
- Maastricht University Medical Center is listed as the lead sponsor on 843 clinical trials in ClinicalTrials.gov, 100 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Maastricht University Medical Center's trials are in Phase 3?
- 25 of Maastricht University Medical Center's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does Maastricht University Medical Center focus on?
- Maastricht University Medical Center's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Breast Cancer, Insulin Resistance, Overweight and Obesity.
- When are Maastricht University Medical Center's next clinical trial readouts?
- Maastricht University Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Biobank Clinical Genetics Maastricht (KG01)”, expected around 2024-03.